Morepen Laboratories Ltd

Morepen Laboratories Ltd | Sector: Pharmaceuticals | ISIN: INE083A01026

₹ 28.85 (2.49%) icon

31 Jan, 2023, 3:42:55 PM
Open
₹ 28.30
Prev. Close
₹ 28.15
Turnover(lac)
₹ 593.46
Day's High
₹ 29.00
Day's Low
₹ 28.00
52 Wk High
₹ 54.80
52 Wk Low
₹ 23.60
Book Value
₹ 14.48
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 1,474.72
P/E
24.91
EPS
1.16
Div. Yield
0.00

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 1/31/2023 3:42:55 PM

    ₹ 28.85 0.70 2.49
  • Open
  • ₹ 28.3
  • Prev. Close
  • ₹ 28.15
  • Turnover(Lac.)
  • ₹ 593
  • Day's High
  • ₹ 29
  • Day's Low
  • ₹ 28
  • 52 Week's High
  • ₹ 54.8
  • 52 Week's Low
  • ₹ 23.6
  • Book Value
  • ₹ 14.48
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 1,474.72
  • P/E
  • 24.91
  • EPS
  • 1.16
  • Divi. Yield
  • 0

Corporate Actions

11 Mar , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Mar , 2022

12:00 AM

09 Feb , 2022

12:00 AM

AGM

Announcement date: 09 Feb , 2022

View Details

Board Meeting

Agenda: Audited Results

View Details

Board Meeting

Agenda: Audited Results

View Details

Board Meeting

Agenda: Audited Results

View Details

05 Sep , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

Board Meeting

Agenda: Audited Results

View Details

Board Meeting

Agenda: Audited Results

View Details

02 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

09 Feb , 2022

12:00 AM

BookCloser

View Details

SHAREHOLDING SNAPSHOT
01 February , 2023 | 07:59 AM

PROMOTER - TOTAL38.22%

Indian: 38.22%

Foreign: 0%

NON-PROMOTER - TOTAL 61.78%

Institutions: 4.64%

Non-Institutions: 57.14%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more

Morepen Laboratories Ltd News and Update

Image not found
  • 20 hours ago |
  • 2:49 PM

The food processing facility, which is spread across nearly 59 acres of land and has a built-up area of 6.5 lakh square feet

Article Image
  • IIFL News Service |
  • 1 day ago |
  • 2:47 PM
Image not found
Image not found
ad IconAd Image

FINANCIALS

No Data Available To Display Chart

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Morepen Laboratories Ltd

  • Sushil Suri

  • Chairman & Managing Director
  • Manoj Joshi

  • Non-Exec. & Independent Dir.
  • Bhupender Raj Wadhwa

  • Non-Exec. & Independent Dir.
  • Sukhcharan singh

  • Non-Exec. & Independent Dir.
  • Vipul Kumar Srivatava

  • Company Sec. & Compli. Officer
  • Sanjay Suri

  • Whole-time Director
  • Praveen Kumar Dutt

  • Non-Exec. & Independent Dir.
  • Savita

  • Non-Exec. & Independent Dir.

Summary

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing... Read More


Reports by Morepen Laboratories Ltd


Reports by Morepen Laboratories Ltd